Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

This study has been completed.
Sponsor:
Collaborator:
University of Cincinnati
Information provided by:
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT00590096
First received: December 27, 2007
Last updated: August 24, 2009
Last verified: January 2007
  Purpose

I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors


Condition
Neuroblastoma
Pheochromocytoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

Resource links provided by NLM:


Further study details as provided by Children's Hospital Medical Center, Cincinnati:

Enrollment: 1380
Study Start Date: January 1991
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Detailed Description:

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Criteria

Inclusion Criteria:

  • Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00590096

Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
University of Cincinnati
Investigators
Principal Investigator: Michael J Gelfand, M.D. Children's Hospital Medical Center, Cincinnati
  More Information

Publications:
Responsible Party: Michael J. Gelfand M.D., Cincinnati Children's Hospital
ClinicalTrials.gov Identifier: NCT00590096     History of Changes
Other Study ID Numbers: CCHMC# 88-12-2
Study First Received: December 27, 2007
Last Updated: August 24, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Medical Center, Cincinnati:
Neuroblastoma
Pheochromocytoma
MIBG

Additional relevant MeSH terms:
Neuroblastoma
Pheochromocytoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Neuroendocrine Tumors
Paraganglioma

ClinicalTrials.gov processed this record on November 27, 2014